MARKET

PRAH

PRAH

PRA Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

147.41
-1.74
-1.17%
After Hours: 147.41 0 0.00% 16:07 02/26 EST
OPEN
150.82
PREV CLOSE
149.15
HIGH
150.82
LOW
146.99
VOLUME
2.23M
TURNOVER
--
52 WEEK HIGH
155.00
52 WEEK LOW
58.67
MARKET CAP
9.46B
P/E (TTM)
48.52
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ICON Plc -- Moody's places ICON's rating under review for downgrade
Rating Action: Moody's places ICON's rating under review for downgradeGlobal Credit Research - 26 Feb 2021Paris, February 26, 2021 -- Moody's Investors Service ("Moody's") has today placed ICON Plc's ("ICON" or "the company") Baa3 long-term issuer rating u...
Moody's · 3h ago
Contract Research Organizations (CROs) Services Market 2020 Business Strategies, Production and Comprehensive Research Study till 2025
Feb 26, 2021 (Heraldkeepers) -- The Global Contract Research Organizations (CROs) Service Market Share is expected to exceed more than US$ 55 Billion by 2024...
Heraldkeepers · 8h ago
PRA Health Sciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 26, 2021 / PRA Health Sciences, Inc. (NASDAQ:PRAH) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 26, 2021 at 9:00 AM Eastern Time.
ACCESSWIRE · 10h ago
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - PAND, PRAH, AEGN, PTVCA, CRHM, CBLI, AKER
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
PR Newswire · 19h ago
Despite risks, Baird raises targets on a pair of merging healthcare firms
Immediate reaction to yesterday's announcement of a big merger of healthcare contract research organizations has Baird raising targets on each company, saying it looks like two good firms with an
Seekingalpha · 22h ago
Robert W. Baird Believes PRA Health Sciences (PRAH) Still Has Room to Grow
In a report released yesterday, Eric Coldwell from Robert W. Baird maintained a Buy rating on PRA Health Sciences (PRAH), with a price target of $160.00.
SmarterAnalyst · 1d ago
Company News for Feb 25, 2021
Zacks.com · 1d ago
Are These Top Health Care Stocks Worth Watching Ahead Of March?
StockMarket.com · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRAH. Analyze the recent business situations of PRA Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRAH stock price target is 139.40 with a high estimate of 160.00 and a low estimate of 110.00.
EPS
Institutional Holdings
Institutions: 531
Institutional Holdings: 66.85M
% Owned: 104.21%
Shares Outstanding: 64.15M
TypeInstitutionsShares
Increased
109
2.32M
New
63
-163.34K
Decreased
98
1.58M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.06%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/President/Chief Executive Officer/Director
Colin Shannon
Chief Financial Officer/Executive Vice President
Michael Bonello
Executive Vice President/Chief Administrative Officer/General Counsel
Christopher Gaenzle
Lead Director/Independent Director
James Momtazee
Independent Director
Jeffrey Barber
Independent Director
Alexander Dickinson
Independent Director
Linda Grais
Independent Director
Glen Stettin
Independent Director
Matthew Young
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About PRAH
PRA Health Sciences, Inc. is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The Company's service offerings include product registration, strategic solutions and early development services.

Webull offers kinds of PRA Health Sciences Inc stock information, including NASDAQ:PRAH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRAH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRAH stock methods without spending real money on the virtual paper trading platform.